NaveenPemmarajuMD

PubMed

• 107 citations
  Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: A single-institution experience
  Kamal Chamoun, Hagop M. Kantarjian, Rami Atallah, Graciela M. Nogueras González, Ghayas C. Issa
  Journal of Hematology & Oncology. 2019-01-03
• 16 citations
  Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
  Shyamala C. Navada, Guillermo Garcia-Manero, Rosalie Odchimar-Reissig, Naveen Pemmaraju, Yesid Alvarado
  Leukemia Research. 2020-05-12
• 6 citations
  First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL).
  Mansour Alfayez, Beenu Thakral, Preetesh Jain, Farhad Ravandi, Alessandra Ferrajoli
  Leukemia & Lymphoma. 2020-01-28

Journal Articles

• Characteristics of Patients with Myeloproliferative Neoplasms with Lymphoma, with or Without JAK Inhibitor Therapy  
  Naveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Srdan Verstovsek, Blood
• International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease  
  Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood

Abstracts/Posters

• Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor P...
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
  Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Myeloproliferative Neoplasm (MPN) Patient Online Questionnaire: Assessing PatientsÍ Disease Knowledge in a Rare Hematologic Malignancy in the Modern Digital Informatio... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis. 
  2019 ASCO Annual Meeting - 6/1/2019
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia – Final Results of a Prospective Phase 2 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Cytogenetic Stratifications in Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant M... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• #HowITweet 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all